A medtech company

A test result is only as reliable as the blood sample behind it.

Protecting blood sample quality from the moment of collection

AG10 Bio is a medtech company developing technology to protect blood sample quality from the moment of collection.

Based at the Precision Health Technologies Accelerator (PHTA), University of Birmingham.

01

The problem

What happens to a blood sample after it is drawn can change the result

A test depends on the sample that reaches the laboratory. Changes between the moment blood is drawn and the moment it is tested can affect that sample.

46–68%

of laboratory errors arise before analysis, across every step from test ordering to sample collection, handling and transport.

Source: Plebani M. Clin Chem Lab Med 2006;44(6):750–9.

Approaches in use today largely try to protect the sample after it has already been collected.

Applied after collection

Existing preservation methods, processing protocols and cold chain are used once a sample has been collected. They cannot reverse changes that have already happened.

Routine checks can miss it

A changed sample can still pass routine laboratory checks, and still be used to generate a result.

AG10 Bio is built around this problem: what happens to a blood sample between the moment it is drawn and the moment it is tested.

02

Our approach

A medtech company focused on pre-analytical sample quality

AG10 Bio is a medtech company focused on pre-analytical blood sample quality: what happens to a blood sample between the moment it is drawn and the moment it is tested.

AG10 Bio is developing technology to protect blood sample quality from the moment of collection. The aim is not to replace diagnostic tests, but to improve the quality of the blood samples those tests rely on.

03

Where it matters

Where changes after collection can affect the result

Changes after collection can affect results in areas such as cancer testing, prenatal screening and routine emergency care.

01

Cancer testing

Many cancer tests rely on a blood sample remaining faithful to the patient after it is drawn. Changes between collection and testing can affect the result.

02

Prenatal screening

Prenatal screening tests that use a blood sample can be affected by changes that occur after collection and before the sample is tested.

03

Emergency and routine care

In emergency departments and routine care, a sample that has changed after collection may still be accepted, and may still affect the result that is reported.

04

Team

Founder-led, with specialist advisory support

Founder & CEO

Mark Rogers

AG10 Bio was founded by Mark Rogers, who has more than 25 years’ experience in diagnostics and life-science commercialisation, including CelLBxHealth, SeraCare and LGC.

Specialist advisory coverage

The company is supported by C-suite and director-level specialist advisors with domain expertise in precision medicine, liquid biopsy and molecular diagnostics, across the following areas.

  • Corporate strategy and leadership
  • Clinical molecular pathology
  • Liquid biopsy assay development and validation
  • Operations and programme delivery

Birmingham base

AG10 Bio is based at the Precision Health Technologies Accelerator (PHTA), University of Birmingham.

An independent test site is in place at the Clinical Immunology Service, University of Birmingham.

05

Contact

If you would like to learn more, please get in touch.